Strategies for eliminating PrPc as substrate for prion conversion and for enhancing PrPSc degradation

Veterinary Microbiology

Volumn 123, Issue 4, 2007, Pages 377-386

  Gilch, Sabine ^a   Nunziante, Max ^a   Ertmer, Alexa ^a   Schätzl, Hermann M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cholesterol; Gleevec; Prion; Prion protein; Therapy; Vaccination

Indexed keywords

APTAMER; BACTERIAL PROTEIN; CELLULAR PRION PROTEIN; CHOLESTEROL; IMATINIB; MEVINOLIN; PEPTIDE APTAMER; PEPTIDE LIBRARY; PRION PROTEIN; PROTEIN TRXA; RECOMBINANT PROTEIN; RNA; SURAMIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; GOLGI COMPLEX; HUMAN; NONHUMAN; PRION DISEASE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; VIRUS INFECTIVITY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; LOVASTATIN; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS; SIGNAL TRANSDUCTION; SURAMIN; VACCINATION;

ESCHERICHIA COLI;

EID: 34447620828     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2007.04.006     Document Type: Article

References (76)

1. Adjou K.T., Demaimay R., Lasmezas C.I., Seman M., Deslys J.P., and Dormont D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res. Virol. 147 (1996) 213-218
2. Adjou K.T., Demaimay R., Deslys J.P., Lasmezas C.I., Beringue V., Demart S., Lamoury F., Seman M., and Dormont D. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J. Gen. Virol. 80 Pt 4 (1999) 1079-1085
3. Arbel M., Lavie V., and Solomon B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J. Neuroimmunol. 144 (2003) 38-45
4. Bate C., Salmona M., Diomede L., and Williams A. Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J. Biol. Chem. 279 (2004) 14983-14990
5. Borchelt D.R., Scott M., Taraboulos A., Stahl N., and Prusiner S.B. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J. Cell Biol. 110 (1990) 743-752
6. Brown P., Liberski P.P., Wolff A., and Gajdusek D.C. Resistance of scrapie infectivity to steam autoclaving after formaldehyde fixation and limited survival after ashing at 360 degrees C: practical and theoretical implications. J. Infect. Dis. 161 (1990) 467-472
7. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., and Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
8. Cashman N.R., and Caughey B. Prion diseases-close to effective therapy?. Nat. Rev. Drug Discov. 3 (2004) 874-884
9. Caughey B., and Race R.E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59 (1992) 768-771
10. Caughey B., and Raymond G.J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 266 (1991) 18217-18223
11. Caughey B., and Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67 (1993) 643-650
12. Caughey B., Race R.E., Ernst D., Buchmeier M.J., and Chesebro B. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J. Virol. 63 (1989) 175-181
13. Caughey B., Kocisko D.A., Raymond G.J., and Lansbury P.T. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem. Biol. 2 (1995) 807-817
14. Conese M., Nykjaer A., Petersen C.M., Cremona O., Pardi R., Andreasen P.A., Gliemann J., Christensen E.I., and Blasi F. Alpha-(2)-macroglobulin meceptor Ldl-receptor-related-protein (Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. 131 (1995) 1609-1622
15. Doh-Ura K., Iwaki T., and Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74 (2000) 4894-4897
16. Dressel O., Kothe R., and Dressel J. Discovery of Germanin. J. Chem. Educ. 38 (1961) 620-621
17. Ellgaard L., Molinari M., and Helenius A. Setting the standards: quality control in the secretory pathway. Science 286 (1999) 1882-1888
18. Enari M., Flechsig E., and Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9295-9299
19. Ertmer A., Gilch S., Yun S.W., Flechsig E., Klebl B., Stein-Gerlach M., Klein M.A., and Schätzl H.M. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J. Biol. Chem. 279 (2004) 41918-41927
20. Gilch S., and Schätzl H.M. Promising developments bringing prion diseases closer to therapy and prophylaxis. Trends Mol. Med. 9 (2003) 367-369
21. Gilch S., Winklhofer K.F., Groschup M.H., Nunziante M., Lucassen R., Spielhaupter C., Muranyi W., Riesner D., Tatzelt J., and Schätzl H.M. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. 20 (2001) 3957-3966
22. Gilch S., Wopfner F., Renner-Muller I., Kremmer E., Bauer C., Wolf E., Brem G., Groschup M.H., and Schätzl H.M. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278 (2003) 18524-18531
23. Gilch S., Nunziante M., Ertmer A., Wopfner F., Laszlo L., and Schätzl H.M. Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP. Traffic 5 (2004) 300-313
24. Gilch S., Kehler C., and Schätzl H.M. The prion protein requires cholesterol for cell surface localization. Mol. Cell. Neurosci. 31 (2006) 346-353
25. Goni F., Knudsen E., Schreiber F., Scholtzova H., Pankiewicz J., Carp R., Meeker H.C., Rubenstein R., Brown D.R., Sy M.S., Chabalgoity J.A., Sigurdsson E.M., and Wisniewski T. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133 (2005) 413-421
26. Gorodinsky A., and Harris D.A. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J. Cell Biol. 129 (1995) 619-627
27. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
28. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., Zinkernagel R.M., Kalinke U., and Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294 (2001) 178-182
29. Horiuchi M., Baron G.S., Xiong L.W., and Caughey B. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. 276 (2001) 15489-15497
30. Ingram D.K. Vaccine development for Alzheimer's disease: a shot of good news. Trends Neurosci. 24 (2001) 305-307
31. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
32. Kaneko K., Vey M., Scott M., Pilkuhn S., Cohen F.E., and Prusiner S.B. COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2333-2338
33. Kaneko K., Zulianello L., Scott M., Cooper C.M., Wallace A.C., James T.L., Cohen F.E., and Prusiner S.B. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10069-10074
34. Kassack M.U., Hofgen B., Lehmann J., Eckstein N., Quillan J.M., and Sadee W. Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. J. Biomol. Screen. 7 (2002) 233-246
35. Klein M.A., Frigg R., Flechsig E., Raeber A.J., Kalinke U., Bluethmann H., Bootz F., Suter M., Zinkernagel R.M., and Aguzzi A. A crucial role for B cells in neuroinvasive scrapie. Nature 390 (1997) 687-690
36. Klein M.A., Kaeser P.S., Schwarz P., Weyd H., Xenarios I., Zinkernagel R.M., Carroll M.C., Verbeek J.S., Botto M., Walport M.J., Molina H., Kalinke U., Acha-Orbea H., and Aguzzi A. Complement facilitates early prion pathogenesis. Nat. Med. 7 (2001) 488-492
37. Ladogana A., Casaccia P., Ingrosso L., Cibati M., Salvatore M., Xi Y.G., Masullo C., and Pocchiari M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol. 73 Pt 3 (1992) 661-665
38. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., and Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91 (1999) 163-168
39. Mabbott N.A., Bruce M.E., Botto M., Walport M.J., and Pepys M.B. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat. Med. 7 (2001) 485-487
40. Mange A., Nishida N., Milhavet O., McMahon H.E., Casanova D., and Lehmann S. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol. 74 (2000) 3135-3140
41. McCain D.F., Wu L., Nickel P., Kassack M.U., Kreimeyer A., Gagliardi A., Collins D.C., and Zhang Z.Y. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases. J. Biol. Chem. 279 (2004) 14713-14725
42. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
43. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., and Kellermann O. Signal transduction through prion protein. Science 289 (2000) 1925-1928
44. Naslavsky N., Shmeeda H., Friedlander G., Yanai A., Futerman A.H., Barenholz Y., and Taraboulos A. Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J. Biol. Chem. 274 (1999) 20763-20771
45. Netzer W.J., Dou F., Cai D., Veach D., Jean S., Li Y., Bornmann W.G., Clarkson B., Xu H., and Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12444-12449
46. Nikles D., Bach P., Boller K., Merten C.A., Montrasio F., Kalinke U., Cichutek K., and Buchholz C.J. Induction of prion protein-specific antibody responses using PrP-retroparticles. Mol. Ther. 9 (2004) S211-S1211
47. Nunziante M., Kehler C., Maas E., Kassack M.U., Groschup M., and Schätzl H.M. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J. Cell Sci. 118 (2005) 4959-4973
48. Pankiewicz J., Prelli F., Sy M.S., Kascsak R.J., Kascsak R.B., Spinner D.S., Carp R.I., Meeker H.C., Sadowski M., and Wisniewski T. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci. 23 (2006) 2635-2647
49. Paquet S., Sabuncu E., Delaunay J.L., Laude H., and Vilette D. Prion infection of epithelial Rov cells is a polarized event. J. Virol. 78 (2004) 7148-7152
50. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., Mehlhorn I.R., Legname G., Wormald M.R., Rudd P.M., Dwek R.A., Burton D.R., and Prusiner S.B. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412 (2001) 739-743
51. Perrier V., Solassol J., Crozet C., Frobert Y., Mourton-Gilles C., Grassi J., and Lehmann S. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrP degradation. J. Neurochem. 89 (2004) 454-463
52. Petzer A.L., Gunsilius E., Hayes M., Stockhammer G., Duba H.C., Schneller F., Grunewald K., Poewe W., and Gastl G. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br. J. Haematol. 117 (2002) 623-625
53. Polymenidou M., Heppner F.L., Pellicioli E.C., Urich E., Miele G., Braun N., Wopfner F., Schätzl H.M., Becher B., and Aguzzi A. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl. Acad. Sci. U.S.A. 101 Suppl. 2 (2004) 14670-14676
54. Priola S.A., Raines A., and Caughey W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science 287 (2000) 1503-1506
55. Prusiner S.B., Scott M.R., DeArmond S.J., and Cohen F.E. Prion protein biology. Cell 93 (1998) 337-348
56. Rosset M.B., Ballerini C., Gregoire S., Metharom P., Carnaud C., and Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol. 172 (2004) 5168-5174
57. Sarnataro D., Paladino S., Campana V., Grassi J., Nitsch L., and Zurzolo C. PrPC is sorted to the basolateral membrane of epithelial cells independently of its association with rafts. Traffic 3 (2002) 810-821
58. Sawyers C.L., McLaughlin J., Goga A., Havlik M., and Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77 (1994) 121-131
59. Schwarz A., Kratke O., Burwinkel M., Riemer C., Schultz J., Henklein P., Bamme T., and Baier M. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350 (2003) 187-189
60. Shyng S.L., Lehmann S., Moulder K.L., and Harris D.A. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J. Biol. Chem. 270 (1995) 30221-30229
61. Sigurdsson E.M., Brown D.R., Daniels M., Kascsak R.J., Kascsak R., Carp R., Meeker H.C., Frangione B., and Wisniewski T. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161 (2002) 13-17
62. Solassol J., Crozet C., and Lehmann S. Prion propagation in cultured cells. Br. Med. Bull. 66 (2003) 87-97
63. Solforosi L., Criado J.R., McGavern D.B., Wirz S., Sanchez-Alavez M., Sugama S., DeGiorgio L.A., Volpe B.T., Wiseman E., Abalos G., Masliah E., Gilden D., Oldstone M.B., Conti B., and Williamson R.A. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303 (2004) 1514-1516
64. Stein C.A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53 (1993) 2239-2248
65. Stein C.A., Khan T.M., Khaled Z., and Tonkinson J.L. Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent. Clin. Cancer Res. 1 (1995) 509-517
66. Supattapone S., Nguyen H.O., Cohen F.E., Prusiner S.B., and Scott M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14529-14534
67. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., Cohen F.E., Prusiner S.B., and Scott M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75 (2001) 3453-3461
68. Tagliavini F., McArthur R.A., Canciani B., Giaccone G., Porro M., Bugiani M., Lievens P.M., Bugiani O., Peri E., Dall'Ara P., Rocchi M., Poli G., Forloni G., Bandiera T., Varasi M., Suarato A., Cassutti P., Cervini M.A., Lansen J., Salmona M., and Post C. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 276 (1997) 1119-1122
69. Taraboulos A., Scott M., Semenov A., Avrahami D., Laszlo L., Prusiner S.B., and Avraham D. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol. 129 (1995) 121-132
70. Uelhoff A., Tatzelt J., Aguzzi A., Winklhofer K.F., and Haass C. A pathogenic PrP mutation and Doppel interfere with polarized sorting of the prion protein. J. Biol. Chem. 280 (2005) 5137-5140
71. Vey M., Pilkuhn S., Wille H., Nixon R., DeArmond S.J., Smart E.J., Anderson R.G., Taraboulos A., and Prusiner S.B. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14945-14949
72. Walmsley A.R., Zeng F., and Hooper N.M. The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. J. Biol. Chem. 278 (2003) 37241-37248
73. Weissmann C., Raeber A.J., Montrasio F., Hegyi I., Frigg R., Klein M.A., and Aguzzi A. Prions and the lymphoreticular system. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 356 (2001) 177-184
74. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., and Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422 (2003) 80-83
75. Winklhofer K.F., and Tatzelt J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol. Chem. 381 (2000) 463-469
76. Yu J.C., Lokker N.A., Hollenbach S., Apatira M., Li J., Betz A., Sedlock D., Oda S., Nomoto Y., Matsuno K., Ide S., Tsukuda E., and Giese N.A. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J. Pharmacol. Exp. Ther. 298 (2001) 1172-1178